Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Probenecid”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 901 records · Page 50Linked to original sources
PubMed1998

Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.

1. Nicotinylalanine, an inhibitor of kynurenine metabolism, has been shown to elevate brain levels of endogenous kynurenic acid, an excitatory amino acid receptor antagonist. This study examined the potential of nicotinylalanine to influence excitotoxic damage to striatal NADPH diaphorase (NADPH-d) and gamma-aminobutyric acid (GABA)ergic neurones that are selectively lost in Huntington's disease. 2. A unilateral injection of the N-methyl-D-aspartate (NMDA) receptor agonist, quinolinic acid, into the rat striatum produced an 88% depletion of NADPH-d neurones. Intrastriatal infusion of quinolinic acid also produced a dose-dependent reduction in striatal GABA content. 3. Nicotinylalanine (2.3, 3.2, 4.6, 6.4 nmol 5 microl(-1), i.c.v.) administered with L-kynurenine (450 mg kg(-1)), a precursor of kynurenic acid, and probenecid (200 mg kg(-1)), an inhibitor of organic acid transport, 3 h before the injection of quinolinic acid (15 nmol) produced a dose-related attenuation of the quinolinic acid-induced loss of NADPH-d neurones. Nicotinylalanine (5.6 nmol 5 microl(-1)) in combination with L-kynurenine and probenecid also attenuated quinolinic acid-induced reductions in striatal GABA content. 4. Nicotinylalanine (4.6 nmol, i.c.v.), L-kynurenine alone or L-kynurenine administered with probenecid did not attenuate quinolinic acid-induced depletion of striatal NADPH-d neurones. However, combined administration of kynurenine and probenecid did prevent quinolinic acid-induced reductions in ipsilateral striatal GABA content. 5. Injection of nicotinylalanine, at doses (4.6 nmol and 5.6 nmol i.c.v.) which attenuated quinolinic acid-induced striatal neurotoxicity, when combined with L-kynurenine and probenecid produced increases in both whole brain and striatal kynurenic acid levels. Administration of L-kynurenine and probenecid without nicotinylalanine also elevated kynurenic acid, but to a lesser extent. 6. The results of this study demonstrate that nicotinylalanine has the potential to attenuate quinolinic acid-induced striatal neurotoxicity. It is suggested that nicotinylalanine exerts its effect by increasing levels of endogenous kynurenic acid in the brain. The results of this study suggest that agents which influence levels of endogenous excitatory amino acid antagonists such as kynurenic acid may be useful in preventing excitotoxic damage to neurones in the CNS.

Alanine↗
PubMedDate not supplied

Clinical evaluation of single-dose oral bacampicillin or ampicillin in therapy of uncomplicated gonorrhea.

Two hundred twenty-eight patients with uncomplicated gonorrhea who returned for follow-up cultures were evaluated for determination of the efficacy of three different regimens of single-dose oral treatment. The regimens included 2.4 g of bacampicillin plus 1.0 g of probenecid, 1.6 g of bacampicillin plus 1.0 g of probenecid, and 3.5 g of ampicillin plus 1.0 g of probenecid. All three regimens were highly effective in the treatment of urogenital and rectal gonorrhea but often failed cure pharyngeal gonorrhea. The highest rate of adverse reactions was reported for patients treated with 2.4 g of bacampicillin plus probenecid. The efficacies of a single oral dose of 1.6 g of bacampicillin (molar equivalent, 1.1 g of ampicillin) plus probenecid and of 3.5 g of ampicillin plus probenecid in the treatment of uncomplicated gonorrhea were equivalent as were the frequencies of adverse reactions to these two regimens.

Ampicillin↗
PubMed1975

Relationship between the transport and toxicity of cephalosporins in the kidney.

Large doses of cephaloridine cause acute necrosis of the proximal renal tubule that can be prevented by probenecid and other organic anions. Although there is little or no net secretion of cephaloridine by the mammalian kidney, the degree of cephaloridine uptake by the cortex of the rabbit kidney is substantial; this uptake is also prevented by probenecid and other organic anions. Cortical concentrations of cephaloridine were measured in control and probenecid-treated animals of different mammalian species. Evidence of cephaloridine trnsport was found in the guinea pig and the rat as well as in the rabbit. The degree of reduction of cortex-to-serum ratios by probenecid (control cortex-to-serum minus probenecid-treated cortex-to-serum ratios) correlated with the sensitivity to the nephrotoxicity of the drug. This degree or reduction was greatest in the rabbit, intermediate in the guinea pig, and least in the rat. In addition, the newborn rabbit, which is more resistant to the toxicity of cephaloridine than the adult, also had significantly lower cortical concentrations of cephaloridine. Finally, the acute tubular necrosis produced by extremely large doses of cefazolin in the adult rabbit was prevented by probenecid. It was concluded (1) that the nephrotoxicity of cephaloridine is related to its renal cortical transport with high intracellular concentrations of drug; and (2) that this relationship between transport and toxicity exists for cefazolin as well, although the toxicity is of a different order of magnitude. The unusual mechanism of cephaloridine transport in the proximal tubule was contrasted with that of the other cephalosporins in an attempt to explain its greater degree of nephrotoxicity.

Acute Kidney Injury↗
PubMed1988

Tubular mechanisms determining the urinary excretion of tritiated prostaglandin E2 in the anaesthetized rat.

1. The renal excretion of arterially injected tritiated prostaglandin E2 ([3H]PGE2) and its metabolites has been examined in the anaesthetized rat before and after the administration of probenecid (an inhibitor of proximal organic acid secretion). [14C]Inulin was employed as a freely filtered, non-reabsorbable marker, while [3H]p-aminohippurate was used to assess the inhibitory effect of probenecid. The experiments allowed us to quantify the tubular delivery, proximal secretion, intratubular metabolism, and tubular reabsorption of [3H]PGE2 by the whole kidney in vivo. 2. Following a single pass through the left kidney 25% of an injected dose of [3H]PGE2 was excreted, although only 1.7% of the injected 3H co-chromatogrammed with cold PGE2. The chemical content of PGE2 in the isotope employed, produced a slight but significant (P less than 0.05) fall (12%) in the single-pass excretion of [14C]inulin. 3. Intravenous probenecid (100 mg kg-1 + 100 mg kg-1 h-1) completely inhibited the proximal tubular secretion of [3H]p-aminohippurate, while the single-pass excretion of [14C]inulin remained unchanged. Probenecid also reduced the blood pressure and urine flow, and decreased the binding of [3H]PGE2 to plasma protein from 59 to 41%. 4. Probenecid administration reduced the single-pass excretion of 3H following an injection of [3H]PGE2 by 65% down to 8.5% of the injected dose. Due to the change in protein binding however, probenecid also increased the filtered load of [3H]PGE2 from 12 to 16% of the injected dose. 5. The following calculations were made concerning the tubular handling of [3H]PGE2 by the whole kidney in vivo. (i) Thirty-five per cent of the injected dose of [3H]PGE2 was secreted by the proximal tubules on a single pass through the kidney, in addition 12% was filtered while 59% was protein bound. (ii) The tubular reabsorption of [3H]PGE2 was 47% of the filtered load. (iii) [3H]PGE2 was subject to a high degree of intratubular metabolism which at a minimum value represented about 50% of the filtered load. The metabolism of [3H]PGE2 also occurred during proximal tubular secretion.

Animals↗
PubMed1992

p-Aminohippurate transport in airways: competitive inhibition.

p-Aminohippurate (PAH) transport in canine tracheal epithelium occurs by a HCO3- -PAH exchange process that is located on the luminal membrane and is inhibited by stilbene derivatives. The effects of increasing concentrations of other organic anions, including probenecid (10-250 microM), dibutyryl adenosine 3',5'-cyclic monophosphate (cAMP; 10-1,000 microM), phenol red (10-250 microM), and urate (25-500 microM), and the organic cation tetraethylammonium bromide (TEA; 250 microM) on PAH transport were examined in canine tracheal epithelium mounted in Ussing chambers. Neither phenol red, urate, nor TEA had any effect on electrophysiological properties or unidirectional or net PAH fluxes. In contrast, beginning at 10 microM, both probenecid and cAMP produced significant decreases in unidirectional and net PAH absorption without change in unidirectional PAH secretion. The initial change in net PAH absorption occurred in the absence of any change in electrophysiological properties. Higher concentrations of both probenecid and cAMP produced further decreases in net PAH absorption and significant changes in electrophysiological properties. Probenecid and cAMP increased the apparent Michaelis constant for PAH absorption without affecting maximum transport rate. The inhibitory constant for probenecid was 1.01 +/- 0.06 x 10(-4) M (mean +/- SE) and for cAMP was 5.18 +/- 0.20 x 10(-4) M. We conclude that PAH transport in canine tracheal epithelium demonstrates competitive inhibition by other organic anions and substrate specificity. We also conclude that the affinity of the exchange transport system is higher for probenecid than for PAH and cAMP.

Animals↗
PubMed1991

The issues of transport multiplicity and energetics pertaining to methotrexate efflux in L1210 cells addressed by an analysis of cis and trans effects of inhibitors.

Studies are described addressing the controversial issue of the multiplicity of efflux routes for [3H]MTX in L1210 cells. We examined efflux multiplicity under conditions that do and do not maintain cellular ATP at the physiological level. In ATP-replete cells, the results delineate a probenecid-, bromosulfophthalein-, and verapamil-inhibitable route that accounts for nearly 90% of [3H]MTX efflux. Efflux of [3H]MTX by this route is inhibited by bromosulfophthalein in the trans orientation only, inhibited by probenecid only when present simultaneously in the cis and trans orientation and inhibited by verapamil only in the cis orientation. The remaining efflux of this folate analogue in ATP-replete cells appears to be mediated by the one-carbon, reduced folate system (MTX influx route), in that it is not inhibited by bromosulfophthalein or verapamil but is inhibited by the N-hydroxysuccinimide ester of MTX, a specific inhibitor of MTX influx, and a 10-fold higher concentration of probenecid than that required to inhibit ATP-dependent efflux. Under these conditions, MTX did not trans-stimulate [3H]MTX efflux. Also, no evidence was obtained for a putative bromosulfophthalein-insensitive, probenecid-inhibitable route for [3H]MTX efflux. In cells depleted to the extent of 90-95% of their ATP by 60-min incubation in medium in the absence of D-glucose and with 10 mM sodium azide, overall efflux of [3H]MTX was markedly reduced and appears to be mediated solely by the MTX influx route. Influx of [3H]MTX was both cis and trans inhibited by probenecid, and efflux under these conditions was markedly inhibited by the N-hydroxysuccinimide ester of MTX and trans-stimulated by MTX. Overall, the results of these studies are consistent with a model for methotrexate transport in L1210 cells derived [Dembo et al., J. Membrane Biol., 78: 9-17, 1984] in the authors' laboratory based solely upon a kinetic analysis of [3H]MTX influx and efflux in ATP-replete and depleted L1210 cells. As such, these new results identify a single ATP-dependent efflux route as the bromosulfophthalein-, probenecid-, and verapamil-inhibitable route in L1210 cells under conditions that maintain ATP levels at maximum.

Adenosine Triphosphate↗
PubMed1994

[Reduced glutathione and L-cysteine in endotoxic shock in the rat].

BACKGROUND: Reduced Glutathione (GSH) is a well known physiological antioxidant, that would protect against lethal effects of endotoxin. However, the site of the action of GSH can be intracellular (transmembrane passage of constitutive amino acids) or extracellular (membrane thiols). AIM OF THE WORK: To search if L-cysteine (one of three constitutive amino acids of GSH) protects against endotoxin as GSH and to search if inhibition of transmembrane passage of GSH and L-cysteine by Probenecid affects that protection. MATERIALS AND METHODS: Rats injected (n = 99) with a lethal dose of endotoxin (BACTO, DIFCO lab. 0111:B4 10 mg/kg ip) immediately after received: (a) Saline solution; (b) GSH 500 mg/kg; (c) L-Cysteine 0.25 g/kg; (d) Probenecid 25 mg/kg in 20% Ethanol plus GSH 500 mg/kg; (e) Probenecid 25 mg/kg in 20% Ethanol; (f) 20% Ethanol. The administration of Saline solution, GSH, L-cysteine was repeated two hours later. Injection volume was 0.5 ml ip. Survival rate of each group of rats was evaluated 6, 12 and 24 hours after endotoxin injection. Survival was compared with that of the control group by Fisher test. RESULTS: GSH and L-cysteine significantly increase survival if compared to all other treatments (respectively p < 0.002 and p < 0.001 at 12 hours; p < 0.005 and p < 0.0002 at 24 hours). Probenecid nullifies the survival increase caused by GSH. Probenecid alone or Ethanol alone show a survival rate not significantly different in respect to control group. CONCLUSIONS: Protection exerted by GSH against fatal effects of endotoxin is also provided by one of its constituent amino acids (L-cysteine) and is inhibited by Probenecid. So we can infer that such an antioxidant action happens at an intracellular site. Need of high doses of GSH and L-cysteine can be due to the necessity of a strong concentration gradient between extra and intracellular sites.

Animals↗
PubMed1980

CSF monoamine metabolites in child and adult psychiatric patients. A developmental perspective.

Concentrations of acid metabolites of dopamine and serotonin were measured in lumbar CSF of a diagnostically heterogeneous group of 154 psychiatric patients following oral probenecid loading. The patients ranged in age from 2 to 67 years old. No patients had received psychoactive medications for at least two weeks prior to the lumbar puncture. Children had higher mean CSF homovenillic acid (HVA) levels, higher mean CSF HVA-probenecid ratios, higher CSF HVA-log probenecid ratios, and lower mean CSF probenecid levels than adults. Age was negatively correlated with CSF HVA level and with CSF HVA-probenecid ratio. These correlations were more pronounced in male patients than in female patients.

Adolescent↗
PubMed2001

Identification of an organic anion transport system in the human colon carcinoma cell line HT29 clone 19A.

The human colon carcinoma cell line HT29 c1.19A was studied for organic anion transporter activity by determining intracellular fluo-3 and fura-red accumulation and by measuring fluo-3 efflux. Modulators of organic anion transport systems were used to identify the transporters that are involved in dye extrusion. Addition of probenecid to the dye-loading medium, containing 10 microM fluo-3/AM and fura-red/AM, resulted in a dose-dependent increase in fluo-3 and fura-red accumulation in the cells. The increase in fluo-3 accumulation in the cells in the presence of probenecid was explained by the inhibitory effect of this compound on fluo-3 efflux. Fluo-3 efflux from the cells was also inhibited by sulfinpyrazone, another inhibitor of organic anion transport. Substrates of renal probenecid-sensitive organic anion exchange mechanisms as well as modulators of multidrug resistance associated protein (MRP) activity did not influence fluo-3 extrusion rates. However, reducing intracellular ATP contents completely blocked fluo-3 extrusion. Moreover, MK571, an inhibitor of MRP, significantly stimulated dye accumulation, whereas inhibitors of the multidrug resistance gene (MDR1) product Pglycoprotein, cyclosporin A and verapamil, did not. As probenecid inhibits fluo-3 efflux across the apical membrane of cells grown on permeable supports, we conclude that a probenecid-sensitive organic anion transporter is present in the apical membrane of HT29 c1.19A cells. This organic anion transport system differs from MDRI and MRP2.

ATP Binding Cassette Transporter, Subfamily B, Mem↗
PubMed1987

The effect of valproic acid on the 5-hydroxyindoleacetic, homovanillic and lactic acid levels of cerebrospinal fluid.

In this study the cisternal cerebrospinal fluid (CSF) contents of 5-hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) were sequentially measured in free-moving rats which were administered 50-500 mg X kg-1 valproic acid. Animals receiving 100-500 mg X kg-1 valproic acid showed significant increases in CSF 5-HIAA and HVA content, with maximal accumulation rates of 1.80-2.10 and 0.25-0.30 nmol X ml-1 X h-1, respectively, being reached at the 250-mg X kg-1 dose. The combination of valproic acid 500 mg X kg-1 and probenecid 300 mg X kg-1 failed to increase the accumulation rates of 5-HIAA and HVA over those seen with valproic acid 500 mg X kg-1 or probenecid 300 mg X kg-1 alone. This pattern of change indicates that valproic acid and probenecid share a common site of action in blocking the clearance of 5-HIAA and HVA from CSF. The tranquillizer diazepam produced progressive increases in CSF 5-HIAA and HVA content which suggested a similar action to that of valproic acid and probenecid. The anticonvulsants phenytoin and phenobarbital produced selective increases in 5-HIAA, whereas the tranquillizer chlorpromazine produced proportionally larger increases in HVA, changes which seem to indicate a more selective effect of these drugs on the serotonergic or dopaminergic systems, respectively. Valproic acid was associated with increases in CSF lactate which occurred in the absence of similar increases of blood or tissue lactate. This indicated that valproic acid, like probenecid, can inhibit the monocarboxylic acid transport system which removes lactate from the CSF.

Animals↗
PubMed1985

The dynamics of dopamine metabolism in the rat superior cervical, coeliac and mesenteric ganglia.

Dopamine (DA) metabolism was compared in rat superior cervical ganglion, coeliac ganglion, mesenteric ganglion and adrenal medulla. Substantial amounts of DA, 3-4 dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were found in all the above structures. The proportion of DA metabolites over total adrenergic compounds increased from the superior cervical (22 +/- 2.2%) to the mesenteric ganglia (37 +/- 1.4%) and was much higher in ganglia (30 +/- 1.6%) than in adrenal medulla (1.1 +/- 0.3%). The turnover rates of DOPAC and HVA were calculated in sympathetic ganglia after pargyline (75 mg/kg i.p.) or probenecid (200-500 mg/kg i.p.). After pargyline, the DOPAC levels decreased faster than HVA levels in all ganglia. The corresponding half-lives and calculated turnover rates were: about 4 and 10 min and 100 and 40 pmol/mg protein per h for DOPAC and HVA respectively. No differences were observed between the three ganglia. After probenecid, DOPAC accumulated in all the ganglia in a dose-dependent way; HVA accumulated in the superior cervical and coeliac ganglia but not in the mesenteric ganglion. As in central areas, the turnover rates of DOPAC and HVA calculated on the basis of the greatest accumulation of acidic levels after probenecid were much smaller than those obtained after pargyline. Probenecid increased DOPAC levels in adrenal medulla, but the concomitant changes in DA and epinephrine (E) amounts suggest that probenecid was able to enhance adrenomedullary activity.(ABSTRACT TRUNCATED AT 250 WORDS)

3,4-Dihydroxyphenylacetic Acid↗
PubMed1986

Renal handling of uric acid in gout: impaired tubular transport of urate not dependent on serum urate levels.

Metabolic studies were conducted in 56 patients with primary gout and in ten normal subjects to assess differences in the tubular transport mechanisms of urate. Renal handling of uric acid was examined by means of pyrazinamide and probenecid tests at increased and pharmacologically reduced serum urate concentrations in both groups. Patients with gout showed similar serum urate levels and glomerular filtration rates than controls at both serum urate levels. Pyrazinamide decreased urinary uric acid excretion to less than 1.0% of the urate filtered load in both groups at increased and diminished serum urate concentrations. The maximum uricosuric response promoted by probenecid at high serum urate levels was (mean +/- SD) 3,707 +/- 443 micrograms/min/1.73 m2 in controls and 2,215 +/- 738 micrograms/min/1.73 m2 in patients with gout (P less than 0.01). Forty-four patients had a daily uric acid excretion rate below 700 mg/1.73 m2, and all of them showed a diminished uricosuric response to probenecid. When serum urate was reduced in normal subjects and 30 patients to a mean of 2.1 and 2.3 mg/dL, respectively, probenecid elicited a significantly lower urate excretion rate in gout (532 +/- 202 micrograms/min/1.73 m2) than in controls (922 +/- 136 micrograms/min/1.73 m2; P less than 0.01). Among these 30 patients examined in their basal state and at decreased serum urate levels, uric acid excretion following probenecid was normal in six and diminished in 24 in both situations. The difference between maximum uricosuria and basal urate excretion was not increased in gouty patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed2005

Carrier-mediated processes at several rat brain interfaces determine the neuropharmacokinetics of morphine and morphine-6-beta-D-glucuronide.

We investigated whether capacity-limited transport processes were involved in morphine and morphine-6-beta-D-glucuronide (M6G) neuropharmacokinetics, at the level of the blood-brain barrier (BBB), the brain extra- and intra-cellular fluids (bECF/bICF), and the bECF/cerebrospinal fluid (CSF) interfaces. We performed transcortical retrodialysis in the rat, by perfusing morphine or M6G through the microdialysis probe in the presence or absence of probenecid. We measured for each compound the in vitro and in vivo (R(D)) probe recoveries. The in vivo R(D), which takes into account the permeability of the tissue surrounding the probe, informs about the morphine and M6G distribution capabilities from bECF to adjacent fluids (bICF, CSF, plasma). We also measured plasma and CSF concentrations at three time points after having added probenecid or not. Finally, we tested several pharmacokinetic models, assuming first-order or capacity-limited processes at each brain interface, to describe experimental morphine and M6G concentrations previously obtained in rat plasma and brain fluids. We found that morphine distributes more easily outside bECF than M6G. Adding probenecid caused a 2-fold decrease and a 1.3-fold increase in morphine and M6G R(D), respectively, and 30 min after adding probenecid, plasma and CSF concentrations increased for M6G but not for morphine. The pharmacokinetic model that gave the best fit included capacity-limited processes at the BBB and bECF/bICF interface for morphine and at the BBB and bECF/CSF interface for M6G. In conclusion, morphine accumulates into brain cells thanks to a probenecid-sensitive transporter located at the bECF/bICF interface, whereas M6G is trapped in bECF thanks to transporters located at the BBB and the bECF/CSF interface.

Algorithms↗
PubMed2000

Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter.

The antifolate drug methotrexate is mainly eliminated from the body by renal tubular secretion via organic anion transporters. In clinical situations, severe methotrexate toxicity, due to an increase in serum concentrations, was observed after coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) or probenecid. In this study, we examined the effects of NSAIDs and probenecid on methotrexate transport via the rat renal organic anion transporter rOAT1, using Xenopus laevis oocytes. [3H]Methotrexate uptake was markedly stimulated in the rOAT1 cRNA-injected oocytes, and this uptake was inhibited by probenecid and various NSAIDs, whereas the influence of salicylate was less. The Dixon plots showed that probenecid, indomethacin and salicylate competitively inhibited rOAT1 with apparent K(i) values of 15.8 microM, 4.2 microM and 1.0 mM, respectively. These findings demonstrate that rOAT1 is the major site of the transporter-mediated interaction between methotrexate and NSAIDs and/or probenecid, leading to a decrease in renal excretion of methotrexate.

Animals↗
PubMed1993

Assessment of valproic acid serum-cerebrospinal fluid transport by microdialysis.

The systemic disposition and serum-cerebrospinal fluid (CSF) translocation of valproic acid (VPA) were examined in rats after administration of VPA as a bolus, as a continuous infusion, or with probenecid. VPA in CSF was monitored continuously by in vivo microdialysis. Both prolonged VPA infusion and probenecid pretreatment increased the Km for saturable VPA elimination and decreased intrinsic hepatic clearance, perhaps due to competition of probenecid or accumulated VPA metabolites for glucuronidation or depletion of hepatic UDP-glucuronic acid. The CSF/serum VPA ratio increased rapidly initially, then decreased with time throughout the remainder of the experiment in all three groups. This time- and/or concentration-dependent behavior suggested that the rate of CSF penetration increased disproportionately with increasing serum VPA and could be described by a kinetic model incorporating a concentration-dependent first-order rate constant for VPA influx into CSF. Under all experimental conditions, the VPA efflux from CSF appeared to be saturable; an increase in the Michaelis constant for efflux was observed following probenecid pretreatment and during VPA infusion, suggesting competitive inhibition of transport by probenecid and derived metabolites of VPA, respectively. The mechanisms responsible for asymmetric VPA transport between serum and CSF, in particular the apparent concentration-dependent change in the rate constant governing CSF penetration, remain to be elucidated.

Animals↗
PubMed1977

Effect of pharmacological inhibitors on urate transport during induced uricosuria.

1. The effect on urate excretion of administration of probenecid and pyrazinamide was observed in normal subjects under control conditions and after induction of uricosuria by exogenous urate loading by ribonucleic acid feeding in seven subjects, by volume loading with hypertonic sodium chloride solution infusion in 11 subjects and by partial inhibition of net urate reabsorption with uricosuric drugs in 20 subjects. 2. After ribonucleic acid feeding, the uricosuric response to probenecid was intact and ribonucleic acid feeding did not produce uricosuria after pyrazinamide. 3. After volume loading, the uricosuric response to probenecid was again intact, but infusion of sodium chloride solution still produced uricosuria after pyrazinamide administration. 4. After uricosuric drugs, the uricosuric response to probenecid was diminished. 5. These responses to probenecid and pyrazinamide may reflect different mechanisms of uricosuria. Response to pharmacological inhibitors of urate reabsorption or urate secretion may be useful for classification of induced and clinical uricosuric states.

Adult↗
PubMedDate not supplied

Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites.

The role of multidrug resistance-associated protein 2 (MRP2) on the intestinal disposition and hepatobiliary elimination of tenofovir disoproxil fumarate (DF) and its metabolites [tenofovir (mono)ester and tenofovir] was studied in the Caco-2 system, Ussing chambers and rat in-situ efflux experiments. In the Caco-2 model and Ussing chambers, no statistically significant differences in transport could be observed when the MRP inhibitor probenecid was included. In Ussing chambers, transport was also similar when using intestinal tissue from MRP2-deficient rats. After intravenous administration of tenofovir DF, the excretion of tenofovir [(mono)ester] in bile was significantly decreased in MRP2-deficient rats and in rats treated with probenecid. The area under the blood concentration-time curve was increased in MRP2-deficient rats [1.0+/-0.1 and 0.36+/-0.03 microM.min-1 for tenofovir and tenofovir (mono)ester, respectively] and rats treated with probenecid (1.42+/-0.04 and 0.36+/-0.02 microM.min-1) compared with control rats (0.64+/-0.05 and 0.15+/-0.06 microM.min-1). The appearance of tenofovir [(mono)ester] in intestinal perfusate was similar in control rats upon co-administering probenecid or when using MRP2-deficient rats. In conclusion, MRP2 appeared to have no modulatory effect on the intestinal disposition of tenofovir and tenofovir (mono)ester. However, inhibition (probenecid) or the total absence of MRP2 (MRP2-deficient rats) significantly reduced hepatobiliary elimination, which was accompanied by increased systemic exposure.

Adenine↗
PubMed1980

Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with progressive myoclonus epilepsy.

The possibility of disturbed dopamine and serotonin metabolism in the progressive myoclonus epilepsy (PME) occurring in Finland (a type of PME without Lafora bodies) was examined. Both basal concentrations of HVA and 5-HIAA in the CSF and their increase after oral probenecid administration were studied in 19 PME patients and in 19 age- and sex-matched control patients. The control patients had grand mal epilepsy but not myoclonus or ataxia. The basal value of HVA was significantly reduced and that of 5-HIAA was also slightly reduced in the PME patients as compared to the values of the epileptic controls or to those of 26 nonepileptic controls. The concentrations of HVA and 5-HIAA also seemed to correlate with the severity of the PME. The most severely affected patients had generally the lowest values. After oral probenecid this trend was also seen when the increases of HVA and 5-HIAA were expressed per microgram CSF probenecid, i.e. the mildly affected PME group showed higher increases in response to probenecid than the most severely affected PME group. The PME patients had higher probenecid levels in the CSF than the epileptic controls.

Adult↗